Beth

Oppenheimer Further Expands Public Finance Banking Team with Appointment of Frank Sanchez Reed As Head of the Southwest Region

Retrieved on: 
Tuesday, March 12, 2024
Momentum, University, Public finance, UBS, Merrill (company), Hospital, Acquisition, Head, Morgan Stanley, City, Senior, Water, Beth, Hires, Oppenheimer Holdings

NEW YORK, March 12, 2024 /PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer) — a leading financial services firm and a subsidiary of Oppenheimer Holdings (NYSE: OPY) — announced today that Frank Sanchez Reed has joined the Public Finance team as Managing Director, Head of the Southwest Region, where he will focus on large issuer coverage and strategy, including in California. He is based in Texas and will report to Elizabeth (Beth) Coolidge, the recently appointed Head of Public Finance.

Key Points: 
  • He is based in Texas and will report to Elizabeth (Beth) Coolidge, the recently appointed Head of Public Finance.
  • "I'm happy to welcome Frank to Oppenheimer," said Coolidge, a Managing Director who leads the Public Finance team from Chicago.
  • Previously, he served as Head of the Central Region at UBS, leading the firm's public finance business in nine states.
  • Earlier in his career, Reed worked at Morgan Stanley, Merrill Lynch and managed J.P. Morgan's public finance business in Texas.

Nicholas Mastroianni II to Receive Knighthood in the Royal Order of Francis I

Retrieved on: 
Friday, February 9, 2024
Beth, Education, Royal order (Belgium), Leukemia, Bourbon, AIDS, Organization, The Ritz-Carlton Hotel Company, Dynasty, Science, Organic, Nursing

NAPLES, Fla., Feb. 9, 2024 /PRNewswire/ -- In a distinguished ceremony on February 11, 2024, at The Ritz-Carlton in Naples, Nicholas "Nick" Mastroianni II will be knighted in the Royal Order of Francis I. The Order, established by the Royal House of Bourbon two centuries ago, honors individuals in various fields including business, science, and education for their monumental contributions to society. 

Key Points: 
  • NAPLES, Fla., Feb. 9, 2024 /PRNewswire/ -- In a distinguished ceremony on February 11, 2024, at The Ritz-Carlton in Naples, Nicholas "Nick" Mastroianni II will be knighted in the Royal Order of Francis I.
  • The Order, established by the Royal House of Bourbon two centuries ago, honors individuals in various fields including business, science, and education for their monumental contributions to society.
  • "I am honored to receive this distinction from such a historic group as the Royal Order of Francis I which has recognized many great individuals," said Mr. Mastroianni.
  • The ceremony will celebrate Nicholas Mastroianni II alongside eleven other eminent individuals from Florida.

Oppenheimer Further Expands Public Finance Banking Team with Appointments of Kristin Stephens and David Moffett

Retrieved on: 
Thursday, February 8, 2024
Build, Growth, ABN AMRO, Holocene, Head, History, Beth, Jefferies, PwC, AMRO Bank, Accenture, Quality of life, Space, ABN, Public finance, J. P. Morgan, Acquisition, Oppenheimer Holdings, BofA Securities, Bank, UBS, Executive officer, Management

NEW YORK, Feb. 8, 2024 /PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer) — a leading financial services firm and a subsidiary of Oppenheimer Holdings (NYSE: OPY) — announced today that Kristin Stephens and David Moffett have joined the Public Finance team as Managing Directors. Ms. Stephens will be based in New York and serve as Head of the Northeast Region while Mr. Moffett will work out of Atlanta and be Head of the Southeast Region. Each will report to Elizabeth (Beth) Coolidge, the newly appointed Head of Public Finance.

Key Points: 
  • Each will report to Elizabeth (Beth) Coolidge, the newly appointed Head of Public Finance.
  • "We are thrilled to have Kristin and David join our team," said Coolidge, who leads the Public Finance team from Chicago.
  • These appointments bolster Oppenheimer's Public Finance team, which includes approximately 25 professionals.
  • I am excited to join such a forward-thinking team and to help enhance Oppenheimer's Public Finance capabilities in the Southeast Region."

Oppenheimer Names Elizabeth Coolidge Head of Public Finance

Retrieved on: 
Tuesday, January 16, 2024
Oppenheimer Holdings, Woman, UBS, The Bond Buyer, Head, Beth, Acquisition, Investment banking, Public finance

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer) — a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) — announced today that it has named Elizabeth (Beth) Coolidge as Head of Public Finance. Based in Chicago, Coolidge will report to Robert Lowenthal, President of Oppenheimer and Head of Investment Banking.

Key Points: 
  • NEW YORK, Jan. 16, 2024 /PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer) — a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) — announced today that it has named Elizabeth (Beth) Coolidge as Head of Public Finance.
  • Based in Chicago, Coolidge will report to Robert Lowenthal, President of Oppenheimer and Head of Investment Banking.
  • Coolidge, who formerly led UBS's Midwest public finance unit for over six years, joins Oppenheimer with UBS colleagues Liberty Ziegahn and Madison Maher.
  • Oppenheimer will now have three women at the helm of its Public Finance, Municipal Underwriting and Municipal Sales departments: Coolidge, Beth Wolchock and Cynthia Henry Pinto, respectively.

NAIC Officers Elected for 2024

Retrieved on: 
Monday, December 4, 2023
National Association, NAIC, Beth, Commissioner, Insurance

ORLANDO, Fla., Dec. 4, 2023 /PRNewswire/ -- Members of the National Association of Insurance Commissioners (NAIC) elected the 2024 officers at the conclusion of the NAIC Fall National Meeting in Orlando today.

Key Points: 
  • ORLANDO, Fla., Dec. 4, 2023 /PRNewswire/ -- Members of the National Association of Insurance Commissioners (NAIC) elected the 2024 officers at the conclusion of the NAIC Fall National Meeting in Orlando today.
  • The newly elected officers will assume their duties on Jan. 1, 2024.
  • The NAIC members also elected 2024 zone officers during the Fall National Meeting.
  • The NAIC is organized into four geographical zones, and within each zone, three officers are elected annually by the respective zone members.

Attorney General Issues Citation and Fine Against Beth Israel Lahey Anna Jaques Hospital for Failure to Keep Accurate Time Records of Nurses Who Worked Through Meal Breaks

Retrieved on: 
Tuesday, November 14, 2023
Legislature, Human, Record, Safety, Policy, City, Nursing, Patient safety, MNA, Complaint, Love, ICU, Risk, Hospital, RN, ED, RNS, Patient, Multimedia, Girl Guides, Emergency, AG, Rest, MGL, Beth, Commission, Death, Self-care, Commonwealth, AJH, Failure, National Nurses United, Letter, Motion, Workplace, Health, Mass, Boston

NEWBURYPORT, Mass., Nov. 14, 2023 /PRNewswire/ -- As the registered nurses at Beth Israel Lahey Anna Jaques Hospital (AJH) continue to engage in efforts to address longstanding concerns about the lack of staff and resources to ensure safe working conditions and quality patient care, the Massachusetts Attorney General's office has stepped in to issue a citation and fine against the employer for a manifestation of that situation. 

Key Points: 
  • The AG's office issued a citation and fine totaling $7,500 last week against AJH for violations of Mass.
  • General Law (MGL) ch 149, sections 15 and 19(3), "Failure to keep true and accurate payroll records from 8/14/2022 to 11/3/2023".
  • To try to document this we have: a) Distributed missed meal break log forms in break rooms and nurses stations.
  • Founded in 1903, the Massachusetts Nurses Association is the largest union of registered nurses in the Commonwealth of Massachusetts.

Frazier & Deeter Welcomes Adam Dormuth as Senior Manager in Forensics & Litigation Support

Retrieved on: 
Friday, November 10, 2023
Senior, JD, CPA, CFE, Beth, FD, CVA, Federation, Audit

ATLANTA, Nov. 10, 2023 /PRNewswire-PRWeb/ -- Frazier & Deeter (FD), a Top 50 accounting and advisory firm, is pleased to announce the addition of Adam W. Dormuth, CPA/CFF, CFE, as Senior Manager. Adam brings with him more than a decade of industry experience to the firm's Forensics & Litigation Support Practice.

Key Points: 
  • ATLANTA, Nov. 10, 2023 /PRNewswire-PRWeb/ -- Frazier & Deeter (FD), a Top 50 accounting and advisory firm, is pleased to announce the addition of Adam W. Dormuth, CPA/CFF, CFE, as Senior Manager.
  • Adam brings with him more than a decade of industry experience to the firm's Forensics & Litigation Support Practice.
  • Adam leverages a deep knowledge in forensic accounting, investigations and litigation support, alongside a client-centric approach.
  • "We are delighted to welcome Adam Dormuth to our Forensics & Litigation Support team.

Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, October 19, 2023
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Illinois College, MedImmune, NCI, Molecular biology, AstraZeneca, Beth Israel Deaconess Medical Center, Senior, Macrogen, Princeton University, University, Internal medicine, National Cancer Institute, Carcinoma, Beth, Patient, Human Genome Sciences, Nursing, Immunome, Seagen

Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer.

Key Points: 
  • Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer.
  • Dr. Lechleider brings over 20 years of experience as an academic and industry executive in medical oncology and cancer research.
  • “We are delighted to welcome Bob to our team during an exciting time in Immunome’s growth as we focus on advancing our oncology pipeline into the clinic,” said Dr. Siegall, President and Chief Executive Officer of Immunome.
  • I would like to extend my thanks to Dr. Siegall and the entire Immunome team for welcoming me to the company,” said Bob Lechleider, M.D., Chief Medical Officer of Immunome.

Coherent Announces Appointment of New Directors to the Board

Retrieved on: 
Wednesday, October 4, 2023
University, Human resources, Executive, Veritiv, Qualcomm Inc. v. Broadcom Corp., Senior, Wayne State University, Culture, Qualcomm, Beth, Business, MBA, COHR, Sale, Diebold Nixdorf, Business administration, Laser, Coherent Corp., HR, Michigan State University, NYSE, Fortune 500, Software, Management, Coherence

“I am pleased to welcome Beth and Michelle to the Coherent Board of Directors.

Key Points: 
  • “I am pleased to welcome Beth and Michelle to the Coherent Board of Directors.
  • “Their appointments also reflect our continued commitment to expanding the skillsets of the Board and our sustained drive to enrich the inclusive culture at Coherent.”
    Elizabeth A.
  • With these changes, the Coherent Board will comprise 14 directors.
  • For a complete list of the board members of Coherent, please visit coherent.com/company/board-of-directors .

SURGE Therapeutics Receives FDA Clearance of IND Application to Initiate Phase 1/2a Study of Intraoperative Immunotherapy in Bladder Cancer

Retrieved on: 
Wednesday, January 4, 2023
Research, Surgery, FDA, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Beth, Cancer, Standard of care, Therapy, Drug discovery, Baylor College of Medicine, SURGE, Immunotherapy, Metastasis, Bladder cancer, Patient, Resiquimod, Safety, FDA, IND, NMIBC, Recurrence, TURBT, Survival, Pharmaceutical industry, Urology

“Receiving IND clearance to advance our intraoperative immunotherapy platform into a Phase 1/2a trial in our first indication represents an important milestone as we continue to advance our pipeline,” said Michael Goldberg, Ph.D., CEO & Founder of SURGE.

Key Points: 
  • “Receiving IND clearance to advance our intraoperative immunotherapy platform into a Phase 1/2a trial in our first indication represents an important milestone as we continue to advance our pipeline,” said Michael Goldberg, Ph.D., CEO & Founder of SURGE.
  • “Surgery is presently a physical intervention only, and we believe that it should be a biochemically therapeutic intervention as well.
  • The SURGERx™ platform is designed to improve the efficacy and safety of immunotherapy treatment, concentrating the effective dose where and when it can yield tremendous impact.
  • It also potentially increases the number of addressable patients for highly potent molecules that are currently limited to treatment of accessible lesions via intratumoral injection.